Lepu Biotech

About Lepu Biotech

Lepu Biopharma Co., Ltd. operates as a biopharmaceutical entity with a strategic focus on oncology therapeutics. The company was established on January 19, 2018, as a subsidiary of Lepu Medical, a manufacturer of cardiovascular interventional devices. The founder of the parent Lepu Group, Dr. Pu Zhongjie, also serves as the Chairman for Lepu Biopharma. He holds a doctorate in metal materials and founded Lepu Medical in 1999 after working in the United States.

The company's business model is centered on an integrated, end-to-end platform that spans drug discovery, clinical development, in-house GMP-compliant manufacturing, and commercialization. Revenue is primarily generated from the sale of pharmaceutical products, alongside income from licensing collaborations. A significant milestone was achieved in February 2022, when Lepu Biopharma was listed on the Main Board of the Hong Kong Stock Exchange, raising approximately US$116.1 million. The company recorded its first recurring revenues in 2022 from its drug Pucotenlimab and reported its first-ever profit in the first half of 2025.

Lepu Biopharma is dedicated to addressing unmet medical needs for cancer patients through the development of targeted therapies and immunotherapies, with a particular emphasis on antibody-drug conjugates (ADCs), oncolytic viruses, and monoclonal antibodies. Its core product pipeline includes candidates like MRG003, MRG002, HX008, and LP002. The company's ADC technology platform is a key asset, enabling the design and development of next-generation cancer treatments. Lepu Biopharma operates GMP-compliant manufacturing facilities in Beijing and is expanding its capacity with a new, larger facility in Shanghai. The company pursues a dual strategy of marketing its products through a dedicated sales force in China while also seeking international partnerships and out-licensing opportunities to maximize the global commercial value of its pipeline.